drugset / Trial / NCT04974047
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
Timeline
- Start
- 2021-08-17
- Primary completion
- 2023-04-17
- Completion
- 2024-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | fluorouracil | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |